Pacific Biosciences of California (NASDAQ:PACB) saw a large decrease in short interest in February. As of February 28th, there was short interest totalling 11,726,630 shares, a decrease of 10.8% from the February 15th total of 13,148,601 shares. Approximately 17.2% of the company’s stock are short sold. Based on an average daily volume of 663,252 shares, the days-to-cover ratio is currently 17.7 days.
Shares of Pacific Biosciences of California (NASDAQ PACB) opened at $2.73 on Tuesday. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.55 and a quick ratio of 2.74. The company has a market cap of $356.79, a PE ratio of -3.07 and a beta of 1.54. Pacific Biosciences of California has a one year low of $2.21 and a one year high of $5.70.
Pacific Biosciences of California (NASDAQ:PACB) last posted its quarterly earnings data on Thursday, February 1st. The biotechnology company reported ($0.18) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.20) by $0.02. The firm had revenue of $24.94 million during the quarter, compared to analyst estimates of $21.89 million. Pacific Biosciences of California had a negative net margin of 98.63% and a negative return on equity of 98.98%. The company’s revenue for the quarter was down 3.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.21) EPS. equities research analysts forecast that Pacific Biosciences of California will post -0.67 earnings per share for the current year.
A number of equities analysts have recently issued reports on PACB shares. BidaskClub raised shares of Pacific Biosciences of California from a “strong sell” rating to a “sell” rating in a research report on Thursday, December 21st. Zacks Investment Research cut shares of Pacific Biosciences of California from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company. Pacific Biosciences of California presently has an average rating of “Hold” and a consensus price target of $6.27.
WARNING: This report was posted by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/3258453/pacific-biosciences-of-california-pacb-short-interest-down-10-8-in-february.html.
About Pacific Biosciences of California
Pacific Biosciences of California, Inc designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes.
Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.